Quantum BioPharma Ltd.
QNTM
$3.89
-$0.16-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.80% | -46.17% | |||
| Depreciation & Amortization | -1.55% | -10.94% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.98% | -49.27% | |||
| Operating Income | -24.98% | 49.27% | |||
| Income Before Tax | -271.42% | 22.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -271.42% | 22.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -71.43% | 218.41% | |||
| Net Income | -348.05% | 43.10% | |||
| EBIT | -24.98% | 49.27% | |||
| EBITDA | -26.51% | 50.49% | |||
| EPS Basic | -282.44% | 43.56% | |||
| Normalized Basic EPS | -115.87% | 11.22% | |||
| EPS Diluted | -282.44% | 43.56% | |||
| Normalized Diluted EPS | -115.87% | 11.22% | |||
| Average Basic Shares Outstanding | 17.16% | 0.81% | |||
| Average Diluted Shares Outstanding | 17.16% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||